{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:23Z","timestamp":1794047423314,"version":"4.8.0"},"reference-count":49,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"6","license":[{"start":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T00:00:00Z","timestamp":1674691200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Gain-of-function mutations in the EPAS1\/HIF2A gene have been identified in patients with hereditary erythrocytosis that can be associated with the development of paraganglioma, pheochromocytoma and somatostatinoma. In the present study, we describe a unique European collection of 41 patients and 28 relatives diagnosed with an erythrocytosis associated with a germline genetic variant in EPAS1. In addition we identified two infants with severe erythrocytosis associated with a mosaic mutation present in less than 2% of the blood, one of whom later developed a paraganglioma. The aim of this study was to determine the causal role of these genetic variants, to establish pathogenicity, and to identify potential candidates eligible for the new hypoxia-inducible factor-2 \u03b1 (HIF-2\u03b1) inhibitor treatment. Pathogenicity was predicted with in silico tools and the impact of 13 HIF-2b variants has been studied by using canonical and real-time reporter luciferase assays. These functional assays consisted of a novel edited vector containing an expanded region of the erythropoietin promoter combined with distal regulatory elements which substantially enhanced the HIF-2\u03b1-dependent induction. Altogether, our studies allowed the classification of 11 mutations as pathogenic in 17 patients and 23 relatives. We described four new mutations (D525G, L526F, G527K, A530S) close to the key proline P531, which broadens the spectrum of mutations involved in erythrocytosis. Notably, we identified patients with only erythrocytosis associated with germline mutations A530S and Y532C previously identified at somatic state in tumors, thereby raising the complexity of the genotype\/phenotype correlations. Altogether, this study allows accurate clinical follow-up of patients and opens the possibility of benefiting from HIF-2\u03b1 inhibitor treatment, so far the only targeted treatment in hypoxia-related erythrocytosis disease.<\/jats:p>","DOI":"10.3324\/haematol.2022.281698","type":"journal-article","created":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T03:59:47Z","timestamp":1674705587000},"page":"1652-1666","source":"Crossref","is-referenced-by-count":16,"title":["Comprehensive &lt;i&gt;in silico&lt;\/i&gt; and functional studies for classification of &lt;i&gt;EPAS1\/HIF2A&lt;\/i&gt; genetic variants identified in patients with erythrocytosis"],"prefix":"10.3324","volume":"108","author":[{"given":"Val\u00e9na","family":"Karaghiannis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darko","family":"Maric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Garrec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada","family":"Maaziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Buffet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lo\u00efc","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Antunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Airaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Aral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amandine","family":"Le Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Corbineau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lamisse","family":"Mansour-Hendili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentine","family":"Lesieur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Rimbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabien","family":"Laporte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Delamare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minke","family":"Rab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"B\u00e9zieau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Cassinat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Galacteros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Paule","family":"Gimenez-Roqueplo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelly","family":"Burnichon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Cario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Van Wijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celeste","family":"Bento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Girodon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hoogewijs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betty","family":"Gardie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2023,1,26]]},"reference":[{"key":"48662","doi-asserted-by":"crossref","unstructured":"Pearson TC, Guthrie DL, Simpson J. Interpretation of measured red cell mass and plasma volume in adults: expert panel on radionuclides of the International Council for Standardization in Haematology. Br J Haematol. 1995; 89(4):748-756.","DOI":"10.1111\/j.1365-2141.1995.tb08411.x"},{"key":"48663","doi-asserted-by":"crossref","unstructured":"Wang GL, Semenza GL. Characterization of hypoxia-inducible factor 1 and regulation of DNA binding activity by hypoxia. J Biol Chem. 1993; 268(29):21513-21518.","DOI":"10.1016\/S0021-9258(20)80571-7"},{"key":"48664","doi-asserted-by":"crossref","unstructured":"Appelhoff RJ, Tian YM, Raval RR. Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. J Biol Chem. 2004; 279(37):38458-38465.","DOI":"10.1074\/jbc.M406026200"},{"key":"48665","doi-asserted-by":"crossref","unstructured":"Lando D, Peet DJ, Whelan DA, Gorman JJ, Whitelaw ML. Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science. 2002; 295(5556):858-861.","DOI":"10.1126\/science.1068592"},{"key":"48666","doi-asserted-by":"crossref","unstructured":"Wenger RH, Stiehl DP, Camenisch G. Integration of oxygen signaling at the consensus HRE. Sci STKE. 2005; 2005(306):re12.","DOI":"10.1126\/stke.3062005re12"},{"key":"48667","doi-asserted-by":"crossref","unstructured":"Semenza GL, Koury ST, Nejfelt MK, Gearhart JD, Antonarakis SE. Cell-type-specific and hypoxia-inducible expression of the human erythropoietin gene in transgenic mice. Proc Natl Acad Sci U S A. 1991; 88(19):8725-8729.","DOI":"10.1073\/pnas.88.19.8725"},{"key":"48668","doi-asserted-by":"crossref","unstructured":"Scortegagna M, Ding K, Zhang Q. HIF-2alpha regulates murine hematopoietic development in an erythropoietindependent manner. Blood. 2005; 105(8):3133-3140.","DOI":"10.1182\/blood-2004-05-1695"},{"key":"48669","doi-asserted-by":"crossref","unstructured":"Percy MJ, Furlow PW, Lucas GS. A gain-of-function mutation in the HIF2A gene in familial erythrocytosis. N Engl J Med. 2008; 358(2):162-168.","DOI":"10.1056\/NEJMoa073123"},{"key":"48670","doi-asserted-by":"crossref","unstructured":"Gale DP, Harten SK, Reid CD, Tuddenham EG, Maxwell PH. Autosomal dominant erythrocytosis and pulmonary arterial hypertension associated with an activating HIF2 alpha mutation. Blood. 2008; 112(3):919-921.","DOI":"10.1182\/blood-2008-04-153718"},{"key":"48671","doi-asserted-by":"crossref","unstructured":"Martini M, Teofili L, Cenci T. A novel heterozygous HIF2AM535I mutation reinforces the role of oxygen sensing pathway disturbances in the pathogenesis of familial erythrocytosis. Haematologica. 2008; 93(7):1068-1071.","DOI":"10.3324\/haematol.13210"},{"key":"48672","doi-asserted-by":"crossref","unstructured":"Gordeuk VR, Miasnikova GY, Sergueeva AI. Thrombotic risk in congenital erythrocytosis due to up-regulated hypoxia sensing is not associated with elevated hematocrit. Haematologica. 2020; 105(3):e87-e90.","DOI":"10.3324\/haematol.2019.216267"},{"key":"48673","doi-asserted-by":"crossref","unstructured":"Pacak K, Chew EY, Pappo AS. Ocular manifestations of hypoxia-inducible factor-2\u03b1 paraganglioma-somatostatinomapolycythemia syndrome. Ophthalmology. 2014; 121(11):2291-2293.","DOI":"10.1016\/j.ophtha.2014.06.019"},{"key":"48674","doi-asserted-by":"crossref","unstructured":"Vaidya A, Flores SK, Cheng Z-M. EPAS1 mutations and paragangliomas in cyanotic congenital heart disease. N Engl J Med. 2018; 378(13):1259-1261.","DOI":"10.1056\/NEJMc1716652"},{"key":"48675","doi-asserted-by":"crossref","unstructured":"Zhuang Z, Yang C, Lorenzo F. Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia. N Engl J Med. 2012; 367(10):922-930.","DOI":"10.1056\/NEJMoa1205119"},{"key":"48676","doi-asserted-by":"crossref","unstructured":"Ta\u00efeb D, Barlier A, Yang C. Somatic gain-of-function HIF2A mutations in sporadic central nervous system hemangioblastomas. J Neurooncol. 2016; 126(3):473-481.","DOI":"10.1007\/s11060-015-1983-y"},{"key":"48677","doi-asserted-by":"crossref","unstructured":"Buffet A, Smati S, Mansuy L. Mosaicism in HIF2A-related polycythemia-paraganglioma syndrome. J Clin Endocrinol Metab. 2014; 99(2):E369-373.","DOI":"10.1210\/jc.2013-2600"},{"key":"48678","doi-asserted-by":"crossref","unstructured":"Tarade D, Robinson CM, Lee JE, Ohh M. HIF-2\u03b1-pVHL complex reveals broad genotype-phenotype correlations in HIF-2\u03b1-driven disease. Nat Commun. 2018; 9(1):3359.","DOI":"10.1038\/s41467-018-05554-1"},{"key":"48679","doi-asserted-by":"crossref","unstructured":"Taylor JC, Martin HC, Lise S. Factors influencing success of clinical genome sequencing across a broad spectrum of disorders. Nat Genet. 2015; 47(7):717-726.","DOI":"10.1038\/ng.3304"},{"key":"48680","doi-asserted-by":"crossref","unstructured":"Orlando IMC, Lafleur VN, Storti F. Distal and proximal hypoxia response elements cooperate to regulate organ-specific erythropoietin gene expression. Haematologica. 2020; 105(12):2774-2784.","DOI":"10.3324\/haematol.2019.236406"},{"key":"48681","doi-asserted-by":"crossref","unstructured":"Storti F, Santambrogio S, Crowther L. A novel distal upstream hypoxia response element regulating oxygendependent erythropoietin gene expression. Haematologica. 2014; 99(4):e45-e48.","DOI":"10.3324\/haematol.2013.102707"},{"key":"48682","doi-asserted-by":"crossref","unstructured":"Wiel L, Baakman C, Gilissen D, Veltman JA, Vriend G, Gilissen C. MetaDome: pathogenicity analysis of genetic variants through aggregation of homologous human protein domains. Human Mutation. 2019; 40(8):1030-1038.","DOI":"10.1002\/humu.23892"},{"key":"48683","doi-asserted-by":"crossref","unstructured":"Baux D, Van Goethem C, Ardouin O. MobiDetails: online DNA variants interpretation. Eur J Hum Genet. 2021; 29(2):356-360.","DOI":"10.1038\/s41431-020-00755-z"},{"key":"48684","doi-asserted-by":"crossref","unstructured":"Richards S, Aziz N, Bale S. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015; 17(5):405-424.","DOI":"10.1038\/gim.2015.30"},{"key":"48685","doi-asserted-by":"crossref","unstructured":"Koay TW, Osterhof C, Orlando IMC. Androglobin gene expression patterns and FOXJ1-dependent regulation indicate its functional association with ciliogenesis. J Biol Chem. 2021; 296:100291.","DOI":"10.1016\/j.jbc.2021.100291"},{"key":"48686","doi-asserted-by":"crossref","unstructured":"De Backer J, Maric D, Bosman M, Dewilde S, Hoogewijs D. A reliable set of reference genes to normalize oxygen-dependent cytoglobin gene expression levels in melanoma. Sci Rep. 2021; 11(1):10879.","DOI":"10.1038\/s41598-021-90284-6"},{"key":"48687","doi-asserted-by":"crossref","unstructured":"Lorenzo FR, Yang C, Ng Tang Fui M. A novel EPAS1\/HIF2A germline mutation in a congenital polycythemia with paraganglioma. J Mol Med (Berl). 2013; 91(4):507-512.","DOI":"10.1007\/s00109-012-0967-z"},{"key":"48688","doi-asserted-by":"crossref","unstructured":"Welander J, Andreasson A, Brauckhoff M. Frequent EPAS1\/HIF2\u03b1 exons 9 and 12 mutations in non-familial pheochromocytoma. Endocr Relat Cancer. 2014; 21(3):495-504.","DOI":"10.1530\/ERC-13-0384"},{"key":"48689","doi-asserted-by":"crossref","unstructured":"Oliveira JL, Coon LM, Frederick LA. Genotype-phenotype correlation of hereditary erythrocytosis mutations, a single center experience. Am J Hematol. 2018; 93:1029-1041.","DOI":"10.1002\/ajh.25150"},{"key":"48690","doi-asserted-by":"crossref","unstructured":"Schelker RC, Herr W, Grassinger J. A new exon 12 mutation in the EPAS1 gene possibly associated with erythrocytosis. Eur J Haematol. 2019; 103(1):64-66.","DOI":"10.1111\/ejh.13241"},{"key":"48691","doi-asserted-by":"crossref","unstructured":"Toyoda H, Hirayama J, Sugimoto Y. Polycythemia and paraganglioma with a novel somatic HIF2A mutation in a male. Pediatrics. 2014; 133(6):e1787-1791.","DOI":"10.1542\/peds.2013-2419"},{"key":"48692","doi-asserted-by":"crossref","unstructured":"Favier J, Buffet A, Gimenez-Roqueplo AP. HIF2A mutations in paraganglioma with polycythemia. N Engl J Med. 2012; 367(22):2161-2.","DOI":"10.1056\/NEJMc1211953"},{"key":"48693","doi-asserted-by":"crossref","unstructured":"Comino-Mendez I, de Cubas AA, Bernal C. Tumoral EPAS1 (HIF2A) mutations explain sporadic pheochromocytoma and paraganglioma in the absence of erythrocytosis. Hum Mol Genet. 2013; 22(11):2169-2176.","DOI":"10.1093\/hmg\/ddt069"},{"key":"48694","doi-asserted-by":"crossref","unstructured":"Toledo RA, Qin Y, Srikantan S. In vivo and in vitro oncogenic effects of HIF2A mutations in pheochromocytomas and paragangliomas. Endocr Relat Cancer. 2013; 20(3):349-359.","DOI":"10.1530\/ERC-13-0101"},{"key":"48695","doi-asserted-by":"crossref","unstructured":"D\u00e4rr R, Nambuba J, Del Rivero J. Novel insights into the polycythemia-paraganglioma-somatostatinoma syndrome. Endocr Relat Cancer. 2016; 23(12):899-908.","DOI":"10.1530\/ERC-16-0231"},{"key":"48696","doi-asserted-by":"crossref","unstructured":"Vaidya A, Flores SK, Cheng Z-M. EPAS1 mutations and paragangliomas in cyanotic congenital heart disease. N Engl J Med. 2018; 378(13):1259-1261.","DOI":"10.1056\/NEJMc1716652"},{"key":"48697","doi-asserted-by":"crossref","unstructured":"Abdallah A, Pappo A, Reiss U. Clinical manifestations of Pacak-Zhuang syndrome in a male pediatric patient. Pediatr Blood Cancer. 2020; 67(4):e28096.","DOI":"10.1002\/pbc.28096"},{"key":"48698","doi-asserted-by":"crossref","unstructured":"Pacak K, Jochmanova I, Prodanov T. New syndrome of paraganglioma and somatostatinoma associated with polycythemia. J Clin Oncol. 2013; 31(13):1690-1698.","DOI":"10.1200\/JCO.2012.47.1912"},{"key":"48699","doi-asserted-by":"crossref","unstructured":"Perrotta S, Stiehl DP, Punzo F. Congenital erythrocytosis associated with gain-of-function HIF2A gene mutations and erythropoietin levels in the normal range. Haematologica. 2013; 98(10):1624-1632.","DOI":"10.3324\/haematol.2013.088369"},{"key":"48700","doi-asserted-by":"crossref","unstructured":"Alaikov T, Ivanova M, Shivarov V. EPAS1 p.M535T mutation in a Bulgarian family with congenital erythrocytosis. Hematology. 2016; 21(10):619-622.","DOI":"10.1080\/10245332.2016.1192394"},{"key":"48701","doi-asserted-by":"crossref","unstructured":"Camps C, Petousi N, Bento C. Gene panel sequencing improves the diagnostic work-up of patients with idiopathic erythrocytosis and identifies new mutations. Haematologica. 2016; 101(11):1306-1318.","DOI":"10.3324\/haematol.2016.144063"},{"key":"48702","doi-asserted-by":"crossref","unstructured":"Liu Q, Tong D, Liu G. HIF2A germline-mutation-induced polycythemia in a patient with VHL-associated renal-cell carcinoma. Cancer Biol Ther. 2017; 18(12):944-947.","DOI":"10.1080\/15384047.2017.1394553"},{"key":"48703","doi-asserted-by":"crossref","unstructured":"Percy MJ, Chung YJ, Harrison C. Two new mutations in the HIF2A gene associated with erythrocytosis. Am J Hematol. 2012; 87(4):439-442.","DOI":"10.1002\/ajh.23123"},{"key":"48704","doi-asserted-by":"crossref","unstructured":"Percy MJ, Beer PA, Campbell G. Novel exon 12 mutations in the HIF2A gene associated with erythrocytosis. Blood. 2008; 111(11):5400-5402.","DOI":"10.1182\/blood-2008-02-137703"},{"key":"48705","doi-asserted-by":"crossref","unstructured":"Couv\u00e9 S, Ladroue C, Laine E. Genetic evidence of a precisely tuned dysregulation in the hypoxia signaling pathway during oncogenesis. Cancer Res. 2014; 74(22):6554-6564.","DOI":"10.1158\/0008-5472.CAN-14-1161"},{"key":"48706","doi-asserted-by":"crossref","unstructured":"Lenglet M, Robriquet F, Schwarz K. Identification of a new VHL exon and complex splicing alterations in familial erythrocytosis or von Hippel-Lindau disease. Blood. 2018; 132(5):469-483.","DOI":"10.1182\/blood-2018-03-838235"},{"key":"48707","doi-asserted-by":"crossref","unstructured":"Ladroue C, Carcenac R, Leporrier M. PHD2 mutation and congenital erythrocytosis with paraganglioma. N Engl J Med. 2008; 359(25):2685-2692.","DOI":"10.1056\/NEJMoa0806277"},{"key":"48708","doi-asserted-by":"crossref","unstructured":"Dwight T, Kim E, Bastard K. Functional significance of germline EPAS1 variants. Endocr Relat Cancer. 2020; 28(2):97-109.","DOI":"10.1530\/ERC-20-0280"},{"key":"48709","doi-asserted-by":"crossref","unstructured":"Kamihara J, Hamilton KV, Pollard JA. Belzutifan, a Potent HIF2\u03b1 Inhibitor, in the Pacak-Zhuang Syndrome. N Engl J Med. 2021; 385(22):2059-2065.","DOI":"10.1056\/NEJMoa2110051"},{"key":"48710","doi-asserted-by":"crossref","unstructured":"Yu Y, Yu Q, Zhang X. Allosteric inhibition of HIF-2\u03b1 as a novel therapy for clear cell renal cell carcinoma. Drug Discov Today. 2019; 24(12):2332-2340.","DOI":"10.1016\/j.drudis.2019.09.008"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.281698\/75306","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.281698\/75669","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/10953\/75306","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:03:21Z","timestamp":1794045801000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2022.281698"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,26]]},"references-count":49,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2022.281698","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1,26]]}}}